Kaplan A H, Manchester M, Smith T, Yang Y L, Swanstrom R
Department of Medicine, University of California at Los Angeles 90024, USA.
J Virol. 1996 Sep;70(9):5840-4. doi: 10.1128/JVI.70.9.5840-5844.1996.
The human immunodeficiency virus type 1 protease plays a critical role in the proteolytic processing of precursor polyproteins during virion maturation. Contradictory evidence has been obtained for a possible role for the protease early after infection, i.e., during DNA synthesis and/or integration. We have reexamined this question by using conditional mutants of the protease. In one set of experiments, protease mutants that confer a temperature-sensitive phenotype for processing were used to assess the need for protease activity early after infection. No significant difference from results with wild-type virus was seen when infections were carried out at either 35 or 40 degrees C. In a separate set of experiments, infections were carried out in the presence of a protease inhibitor. In this case, both wild-type virus and a drug-resistant variant were used, the latter as a control to ensure a specific effect of the inhibitor. Infection with either virus was not inhibited at drug concentrations that were up to 10-fold higher than those needed to inhibit intracellular processing by the viral protease. The results obtained by both of these experimental protocols provide evidence that the human immunodeficiency virus type 1 protease does not play a role early after infection.
1型人类免疫缺陷病毒蛋白酶在病毒体成熟过程中对前体多蛋白的蛋白水解加工起着关键作用。关于感染后早期,即DNA合成和/或整合期间蛋白酶可能发挥的作用,已获得相互矛盾的证据。我们通过使用蛋白酶的条件突变体重新审视了这个问题。在一组实验中,赋予加工温度敏感表型的蛋白酶突变体用于评估感染后早期对蛋白酶活性的需求。在35或40摄氏度下进行感染时,与野生型病毒的结果没有显著差异。在另一组实验中,在蛋白酶抑制剂存在的情况下进行感染。在这种情况下,使用了野生型病毒和耐药变体,后者作为对照以确保抑制剂的特异性作用。在高达比抑制病毒蛋白酶细胞内加工所需浓度高10倍的药物浓度下,两种病毒的感染均未受到抑制。通过这两种实验方案获得的结果提供了证据,表明1型人类免疫缺陷病毒蛋白酶在感染后早期不发挥作用。